Medtech Insight RSS Feed - Diabetic Care

L’Oréal Closes Kering Beauté, Clorox Wraps Purell; Beauty Deal Roundup

Eileen Francis — Fri, 03 Apr 2026 23:29:54 +0000

L’Oréal Completes Kering Beauté Deal L’Oréal Groupe has completed its acquisition of Kering SA’s Kering Beauté, including House of Creed, while also formalizing 50-year exclusive licenses for fragranc

LSI Panel Says Women’s Health Breaks Out Of ‘Bikini Box’ As New Business Models Catch Investors’ Eye

Marion Webb — Fri, 03 Apr 2026 22:36:03 +0000

For years, women’s health has been narrowly defined as fertility, pregnancy and a handful of screening tools. At the LSI USA conference in Dana Point, CA, a panel of women’s health company leaders and

FDA Releases Trove Of Data On Use of Real-World Evidence In Device Clearances

Elizabeth Orr — Fri, 03 Apr 2026 21:57:35 +0000

Manufacturers seeking US Food and Drug Administration guidance on how to use real-world evidence (RWE) in device submissions now have a broad range of new examples to draw from. An April 2 report titl

Vedanta’s Phase III For Recurrent C. Diff Gets Nod To Continue

Joseph Haas — Fri, 03 Apr 2026 21:31:22 +0000

Vedanta Biosciences has gotten a go-ahead from the independent data monitoring committee overseeing its RESTORATiVE303 Phase III trial of VE303, a live biotherapeutic product, for prevention of recurr

Acadia CEO Led The Company To A Key Goal In A Challenging Year For Biopharma

Mandy Jackson — Fri, 03 Apr 2026 19:02:35 +0000

Last year was tough for the biopharmaceutical industry as companies struggled to understand the implications of policy changes under the Trump administration, adding another set of challenges for CEOs

No Evidence Of Benefit: Two Trials Prompt Calls to End Routine Use Of J&J’s Impella Heart Pump

Shubham Singh — Fri, 03 Apr 2026 17:08:17 +0000

The clinical evidence base for Johnson & Johnson’s Impella miniaturized heart pumps has been called into question by two randomized trials presented at the American College of Cardiology’s annual

Washington Sleep Doctor Gets Year In Prison For Distributing Recalled Philips CPAP, BiPAP Devices

Elizabeth Orr — Fri, 03 Apr 2026 16:04:12 +0000

A Washington state sleep doctor has been sentenced to a year and a day in prison for distributing recalled Philips Respironics continuous positive airway pressure (CPAP) and BiPAP (Bilevel Positive Ai

Biosimilar Streamlining Takes A Further Step Forward In Europe

Dave Wallace — Fri, 03 Apr 2026 15:00:00 +0000

Almost a year to the day since the European Medicines Agency published a landmark draft reflection paper on streamlining the development and assessment of biosimilar medicines, the agency has formal

Atrogi Bets On Muscle Preservation And Exercise Mimetics To Drive Obesity Push

Sushmita Panda — Fri, 03 Apr 2026 13:02:58 +0000

Sweden‑based Atrogi is targeting a different corner of the obesity market, developing drugs designed to preserve muscle mass and mimic the effects of exercise rather than simply suppressing appetite.

Lipocine’s Oral Formulation Of Zulresso Fails Postpartum Depression Trial

Manas Mishra — Fri, 03 Apr 2026 12:55:17 +0000

Lipocine’s bid to replicate the effects of Sage Therapeutics’ now-discontinued postpartum depression (PDD) drug, Zulresso (brexanolone), in pill form has stumbled at the final hurdle. On April 2, th

US Shields Generics From Tariffs Amid Supply Chain Concerns

Dean Rudge — Fri, 03 Apr 2026 12:30:27 +0000

The Trump administration on April 2 imposed sweeping tariffs on imported pharmaceuticals following a year-long Section 232 national security investigation , while explicitly exempting generic and bio

‘It’s Day And Night’ – Haruvi On How The AAM Has Evolved

Dave Wallace — Fri, 03 Apr 2026 12:20:34 +0000

As chair of the Association for Accessible Medicines since late 2023, Keren Haruvi has helped to steer the US generics and biosimilars industry body through some turbulent times. Speaking to Generics

Hyloris Warns Valacyclovir Launch Could Slip Into 2027

Dean Rudge — Fri, 03 Apr 2026 12:20:20 +0000

Hyloris Pharmaceuticals has warned that its ready-to-use valacyclovir oral liquid program could face delays extending into 2027 following manufacturing setbacks tied to its US regulatory submission. T

GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not

Derrick Gingery — Fri, 03 Apr 2026 12:19:53 +0000

The generic drug user fee program saw spending drop substantially in fiscal year 2025, but the US Food and Drug Administration remains concerned that revenue is not adequate and fee system changes are

Executives On The Move: Five CEOs And Six CFOs Among This Week’s Changes

Fri, 03 Apr 2026 11:07:19 +0000

Glenmark Reshapes US Ryaltris Strategy, Steps Away From Hikma Tie-Up

Anju Ghangurde — Fri, 03 Apr 2026 09:43:38 +0000

Six years after sealing an exclusive licensing agreement with Hikma to commercialize Ryaltris (olopatadine HCl/mometasone furoate nasal spray) in the US, Glenmark has now decided to directly drive bra

Bayer’s Men’s Pre-Conception Health Multivitamin Ad Claims Fail To Launch In NAD Review

Malcolm Spicer — Fri, 03 Apr 2026 02:37:31 +0000

Bayer AG’s US consumer health business provided evidence to support maintaining the brand name for its One A Day Men’s Pre-Conception Health Complete Multivitamin but little else in an industry self-r

LG Builds Global Oncology Ambitions With Novel Frontier Asset

Ian Haydock — Fri, 03 Apr 2026 01:48:27 +0000

South Korea’s LG Chem is furthering its global oncology ambitions through the acquisition of exclusive worldwide development and commercialization rights outside of greater China to FMC-220, US proteo

Renhe Yikang Group Co., Ltd.

Fri, 03 Apr 2026 00:08:05 +0000

http://www.rhykjt.com/

Cellio Therapeutics

Fri, 03 Apr 2026 00:07:35 +0000